Anti-malaria drug artesunate prevents development of amyloid-β pathology in mice by upregulating PICALM at the blood-brain barrier.
Kassandra KislerAbhay P SagareDivna LazicSam BazziErica LawsonChing-Ju HsuYaoming WangAnita RamanathanAmy R NelsonZhen ZhaoBerislav V ZlokovicPublished in: Molecular neurodegeneration (2023)
Artesunate increases PICALM levels and Aβ clearance at the BBB which prevents development of Aβ pathology and functional deficits in mice and holds potential for translation to human AD.